Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gang Dong, Seoul, Korea.
Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
Medicine (Baltimore). 2022 May 13;101(19):e29266. doi: 10.1097/MD.0000000000029266.
Esophagogastroduodenoscopy (EGD) under sedation may result in gastrointestinal (GI) and non-GI complications. However, no previous studies have reported 30-day GI and non-GI complications after diagnostic EGD under sedation.We conducted a retrospective, observational study of 30-day GI and non-GI complication rates after outpatient diagnostic EGD under sedation in subjects ≥18 years between January 2012 and December 2017 based on a common data model database. Thirty-day complication rates were compared with EGD under sedation or not, type of sedation drugs (midazolam only vs midazolam/propofol) and age groups (18-64 year vs ≥65 year) for GI (bleeding and perforation) and non-GI complications (pneumonia, acute myocardial infarction, congestive heart failure and cerebral stroke).In total, 39,910 were performed with sedation (midazolam only, n = 16,033 and midazolam/propofol, n = 23,864) and 22,894 were performed without sedation. Elderly patients significantly favored EGD without sedation (P < .01). GI and non-GI complication rates were similar between EGD under sedation and without sedation (all P > .1) except for acute myocardial infarction rate, which was significantly higher in EGD without sedation than EGD under sedation (1.7/10,000 vs 0.3/10,000 persons, P = .043). All GI and non-GI complications were also similar between the midazolam/propofol and midazolam only groups as well as between young and old patients (all P > .1).Outpatient diagnostic EGD under sedation has an excellent safety profile. In addition, it can be safely performed with midazolam only or midazolam/propofol and in young and old patients.
在镇静下进行食管胃十二指肠镜检查(EGD)可能会导致胃肠道(GI)和非 GI 并发症。然而,以前没有研究报告过在镇静下进行诊断性 EGD 后 30 天的 GI 和非 GI 并发症。我们根据通用数据模型数据库,对 2012 年 1 月至 2017 年 12 月期间 18 岁以上门诊接受镇静下诊断性 EGD 的患者进行了一项回顾性、观察性研究,以评估 30 天 GI 和非 GI 并发症的发生率。GI(出血和穿孔)和非 GI 并发症(肺炎、急性心肌梗死、充血性心力衰竭和脑卒中等)的并发症发生率比较了镇静下和非镇静下 EGD、镇静药物类型(仅咪达唑仑与咪达唑仑/丙泊酚)以及年龄组(18-64 岁与≥65 岁)。总共进行了 39910 次镇静下 EGD(仅咪达唑仑,n=16033;咪达唑仑/丙泊酚,n=23864)和 22894 次非镇静下 EGD。老年患者明显倾向于不接受镇静下 EGD(P<.01)。镇静下和非镇静下 EGD 的 GI 和非 GI 并发症发生率相似(所有 P>.1),但急性心肌梗死发生率不同,非镇静下 EGD 明显高于镇静下 EGD(1.7/10000 与 0.3/10000 人,P=.043)。咪达唑仑/丙泊酚组和仅咪达唑仑组以及年轻患者和老年患者之间的所有 GI 和非 GI 并发症也相似(所有 P>.1)。在镇静下进行门诊诊断性 EGD 具有极好的安全性。此外,它可以安全地使用咪达唑仑或咪达唑仑/丙泊酚,并且可以在年轻和老年患者中进行。